Mahmood Majeed, ZS, explains why measurable AI outcomes in pharma supply chain and manufacturing jumped from 29% to 53%, and how GMP limits and GxP validation shape adoption.
|Articles|July 22, 2016
PTSM: Pharmaceutical Technology Sourcing and Management
- PTSM: Pharmaceutical Technology Sourcing and Management-08-03-2016
- Volume 11
- Issue 8
CSafe Opens Facility in Puerto Rico
Author(s)Pharmaceutical Technology Editors
The company opened a new service center in San Juan, Puerto Rico.
Advertisement
On July 18, 2016, CSafe Global announced that it has opened a new service center in San Juan, Puerto Rico. The company procured multiple 747F charter aircrafts to move multiple CSafe RKN ULDs to the facility. According to CSafe, the containers will be used to support the country’s global manufacturing industry. CSafe’s passive and small active solutions will also be available for use at the new Puerto Rican Facility.
Source:
Articles in this issue
about 10 years ago
Slower Bio/Pharma Investment Could Hurt CDMOs in 2017about 10 years ago
Supply Chain Partner Scrutiny Moves Beyond GMPsabout 10 years ago
Chiral Advances Demonstrate Promise for API Synthesisover 10 years ago
NIST Issues mAb Reference Standardover 10 years ago
EMA Suspends Drugs Due to Flawed Bioequivalence Studiesover 10 years ago
CordenPharma Expands into Oligonucleotide APIsover 10 years ago
Shimadzu System Combines HPLC and UHPLC Methodsover 10 years ago
Catalent to Commercially Supply Palatin FSD Pen Injectorsover 10 years ago
Zenith Appoints Serialization DirectorAdvertisement
Related to this article
Science, circularity, regulation, and technology are reshaping how the industry develops packaging for medicines.
The PharmTech team focused on its coverage of AAPS PharmSci 360 this week, conducting interviews with experts on a range of topics including formulation platforms, AI, amorphous solid dispersions, and animal studies.
Subathra Ramamoorthy, Veranova, on when to escalate to structural elucidation and pair orthogonal techniques when characterizing an impurity.
Manish Baviskar, Hubot CDMO, on ALCOA++ data integrity, model version change control, continuous monitoring, and human sign-off.
The agreement between CDER and OII with allow for coordinated marketing application assessments and inspections.
Manish Baviskar, Hubot CDMO, explains which AI skills validation engineers need first and why AI model updates must go through GMP change control.
Ron Filler, Drug Development Consultants, explains how USP's 1074 revision brings human-relevant safety science to formulators and excipient makers.
Advertisement
Advertisement